Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 7/20 | 0.49 |
| ▸ | MAOA | P21397 | 2/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | PARP15 | Q460N3 | 6/20 | 0.46 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7651036 | 0.82 | MAOA (0.56) | PARP10MAOAMAOBPARP15PDK2 | |
| SCHEMBL3069878 | 0.78 | CHRNA7 (0.49) | — | |
| SCHEMBL18616171 | 0.77 | HRH3 (0.56) | PARP10MAOAMAOBPARP15PDK2 | |
| SCHEMBL18942857 | 0.76 | KDM4C (0.49) | — | |
| SCHEMBL7649580 | 0.76 | MAOA (0.56) | PARP10MAOAMAOBPARP15 | |
| SCHEMBL9273256 | 0.76 | PPARD (0.48) | — | |
| SCHEMBL9403377 | 0.74 | PGR (0.50) | — | |
| SCHEMBL9221653 | 0.74 | PGR (0.43) | PARP10MAOBPDK2 | |
| SCHEMBL345441 | 0.73 | CHRNA7 (0.50) | — | |
| SCHEMBL15839910 | 0.72 | HTR6 (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6482852-B2 | UE TREATING PROLIFERATIVE DISEASE, CANCER, RESTENOSIS, OSTEOPOROSIS, INFLAMMATION, ALLERGIES, OR CARDIOVASCULAR DISEASE; INHIBITION OF SH2-MEDIATED SIGNALING | ARIAD PHARMACEUTICALS, INC. | 2002-11-19 | — | — | US | disclosed |
| US-20020137941-A1 | Ue treating proliferative disease, cancer, restenosis, osteoporosis, inflammation, allergies, or cardiovascular disease; inhibition of SH2-mediated signaling | ARIAD PHARMACEUTICALS, INC. | 2002-09-26 | — | — | US | disclosed |
| EP-1129068-A1 | BICYCLIC SIGNAL TRANSDUCTION INHIBITORS, COMPOSITION CONTAINING THEM AND USES THEREOF | ARIAD PHARMACEUTICALS, INC. (US) | 2001-09-05 | — | — | EP | disclosed |
| WO-2000027802-A1 | BICYCLIC SIGNAL TRANSDUCTION INHIBITORS, COMPOSITIONS CONTAINING THEM & USES THEREOF | ARIAD PHARMACEUTICALS, INC. (US) | 2000-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137941-A1 | Ue treating proliferative disease, cancer, restenosis, osteoporosis, inflammation, allergies, or cardiovascular disease; inhibition of SH2-mediated signaling | GRB2, LCK, PTK2 | PARP10 2644/4885MAOA 3051/4885MAOB 2687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.